Phase 2 Multi-Center, Dose Escalation Trial To Assess The Safety And Effectiveness Of Bucillamine On Urinary Cystine Excretion And Cystine Capacity In Patients With Cystinuria

Trial Profile

Phase 2 Multi-Center, Dose Escalation Trial To Assess The Safety And Effectiveness Of Bucillamine On Urinary Cystine Excretion And Cystine Capacity In Patients With Cystinuria

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 May 2017

At a glance

  • Drugs Bucillamine (Primary)
  • Indications Cystinuria
  • Focus Adverse reactions; Proof of concept
  • Sponsors Revive Therapeutics
  • Most Recent Events

    • 26 Feb 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
    • 26 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 21 Dec 2016 According to a Revive Therapeutics media release, company has engaged NYU School of Medicine as one of the Company's clinical sites in this study and this study is expected to be completed by Q2 of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top